Breaking News
Global News
Chola Securities in News
Sessions News
Economy News
Nifty 50
Sensex
Nifty Bank
Bankex
Nifty 100
BSE Sensex 50
Nifty Financial Services
BSE Sensex Next 50
Nifty Midcap 100
BSE Bharat 22
Nasdaq
DJIA
S&P 500
Hang Seng
Nikkei 225
Straits Times
FTSE 100
KLSE Composite
Jakarta Composite
Exchange Holiday List
Historical Returns
Top Gainers
Top Losers
52 Week High
52 Week Low
Most Active by Value
Most Active by Volume
Out Performer
Under Performer
Advances & Declines
Only Buyers and Sellers
Bulk deal
Block deal
Nifty Futures
Nifty Options
Bank Nifty Futures
Bank Nifty Options
Stock Futures
Stock Options
Increase in OI
Decrease in OI
Highest in OI
Lowest in OI
All Index Futures
Most Active Contracts
Most Active Call
Most Active Put
Solutions
Platforms
Research
More
Markets
Become a partner
Macitentan tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospitalization for PAH.
Macitentan tablets, 10 mg, have an estimated market size of $1,180 million for twelve months ending June 2025 according to IQVIA.
The pharmaceutical company has a cumulative total of 224 ANDA approvals (203 final approvals and 21 tentative approvals) from USFDA.
Alembic Pharmaceuticals is a vertically integrated research-driven company that manufactures and markets generic medicines globally.
The company's consolidated net profit jumped 14.6% to Rs 154.38 crore while revenue from operations grew 9.54% to Rs 1,710.72 crore in Q1 June 2025 over Q1 June 2024.
Powered by Capital Market - Live News
on Chola Securities Mobile & Web App.
Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.